AstaReal Inc. is part of AstaReal Holdings Co., Ltd. which is a wholly owned subsidiary of Fuji Chemical Group. AstaReal Inc. is a sales and marketing company servicing North and South America. Our natural astaxanthin is cultivated, grown and harvested in our manufacturing facility in Moses Lake, Washington. As the global demand for natural astaxanthin continues to grow, we will continue to be fully dedicated to ensuring the supply of premium, natural astaxanthin products.
Sales & Marketing Office
3 Terri Lane, Unit 12
Burlington, NJ 08016
7761 Randolph Rd. NE
Moses Lake, WA 98837
The Front Tower Shiba Koen,
12th Floor, 2-6-3 Shiba Koen
Minato-ku, Tokyo 105-0011
AstaReal Natural Astaxanthin—supported by technology and science
Our original facility is located in Gustavsberg, Sweden. In order to keep up with growing demand in North and South American region, we have opened a new, state of the art facility, located in Moses Lake, Washington. With two production facilities, AstaReal is able to offer stable supply through our indoor production technology.
Haematococcus pluvialis is a freshwater microalga belonging to family Chlamydomonadaceae. Strains of the alga extend across habitats ranging from the African lakes to the Arctic snow fields. Typical habitats are ephemeral ponds and rainwater pools, for example, rock pools in the Stockholm archipelago.
Under favorable conditions, the motile, green cells of Haematococcus pluvialis thrive, reproducing primarily by other unfavorable conditions, the cells enter a resting state and become spores with thick cell walls. When transforming into this spore phase, these algae not only store fats as an energy source, but also begin producing and accumulating astaxanthin.
Astaxanthin acts like a force field that protects the nuclear DNA and cell contentfrom oxidation and UVA radiation. The encapsulated form of the algae is calledan aplanospore and in this form, the algae can survive for long periods, evenunder harsh conditions.
|Source||Average Astaxanthin Content|
|Lobster, Crawfish||0.3mg / 100g|
|Salmon||3mg / 100g|
|Krill||4mg / 100g|
|Phaffia Yeast||800mg / 100g|
|Haematococcus Pluvialis Microalgae (Source of AstaREAL Astaxanthin)||6,000mg / 100g|
AstaReal was the first company in the world to commercially produce natural astaxanthin from Haematococcus pluvialis. AstaReal has a production facility in Gustavsberg, Sweden and in Moses Lake, Washington in the United States. Thanks to our high level of expertise and long-term experience in the production of microalgae, we can offer the best quality product with the highest amount of astaxanthin per kilogram of biomass.
The algae is grown in stainless steel photo bioreactors under carefully controlled indoor sterile conditions to enable a more effective, cleaner, and safer process. Our equipment is of the highest quality, and the production is both ISO 9001 and HACCP certified.
Cultivation starts with the “seed” which is enriched with essential nutrients that provide the algae with optimal conditions for rapid growth and proliferation (Green Phase). When the culture has reached its optimum density in the Green Phase, the production of astaxanthin is induced (Red Phase). After harvest, the algae are crushed and finally dried.
The final biomass is a deep-red powder containing a high concentration of astaxanthin. This can then be further refined to create a high purity, raw material ingredient that is used in the manufacture of various products, such as dietary supplements, foods, and cosmetics.
There are over 400 peer reviewed studies on astaxanthin. AstaReal® has been featured in the vast majority of these studies. The clinical database for AstaReal® contains over 50 human studies, including 23 double-blind, placebo-controlled trials, with more than 1,400 participants undergoing treatments lasting from 2 weeks to 6 months. The doses used in these trials ranged from 2 to 45 mg/day. The trials were designed to determine the efficacy, safety, and tolerance of AstaReal® astaxanthin for different doses, treatment periods, study designs, and demographic variables including age, gender, and ethnicity. All studies revealed no adverse effects based on hematological findings, serum chemistry, urinal analysis, and self-report questionnaires.
|Patent Title for Human Health||Patent Number|
|Agents for relieving eye controlling function error||EP 1396264|
|Oral preparation for the prophylactic and therapeutic treatment of Helicobacter sp.infection||US 6262316|
|Medicament for improvement of duration of muscle function or treatment of muscledisorders or diseases||US 6245818|
|Use of xanthophylls for improvement of duration of muscle function or treatment of muscle disorders||CA 2299366|
|Method of increasing the production and improving the quality of semen||US 6410602|
|Method of the prophylactic treatment of mastitis||US 6335015|
|Treatment of dyspepsia||US 6923967|
|Use of xanthophylls astaxanthin e.g. for treatment of autoimmune diseases chronic viral and intracellular bacterial infections||US 6773708|
|Method of inhibiting the expression of inflammatory cytokines and chemokines||US 078040|
|Composition for body fat reduction||JP 5165894|
|Patent Title for Animals||Patent Number|
|Method for increasing the production of/in breeding and production animals in the poultry industry||US 5744502|
|Agent for increasing the production of/in breeding and production mammals||US 6054491|
|Patent Title for Device and Chemical Products||Patent Number|
|Fine algae culture device||US 6348347|
|Method of preventing discoloration of carotenoid pigment and container used therefor||EP 2322579|